These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30900137)

  • 21. Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
    Hall E; Cameron D; Waters R; Barrett-Lee P; Ellis P; Russell S; Bliss JM; Hopwood P;
    Eur J Cancer; 2014 Sep; 50(14):2375-89. PubMed ID: 25065293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
    Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
    Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
    de Gregorio A; Häberle L; Fasching PA; Müller V; Schrader I; Lorenz R; Forstbauer H; Friedl TWP; Bauer E; de Gregorio N; Deniz M; Fink V; Bekes I; Andergassen U; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Blohmer JU; Fehm TN; Heinrich G; Lato K; Beckmann MW; Rack B; Janni W
    Breast Cancer Res; 2020 Oct; 22(1):111. PubMed ID: 33097092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.
    Bines J; Small IA; Sarmento R; Kestelman F; Silva S; Rodrigues FR; Faroni L; Gonçalves A; Ebecken E; Maroun P; Millen E; Bonamino M
    Oncologist; 2020 Sep; 25(9):758-764. PubMed ID: 32476183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG; Gradishar WJ
    Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
    Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
    Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.
    Anand K; Niravath P; Patel T; Ensor J; Rodriguez A; Boone T; Wong ST; Chang JC
    Clin Breast Cancer; 2021 Jun; 21(3):199-204. PubMed ID: 34159901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
    Awada A; Biganzoli L; Cufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    Eur J Cancer; 2002 Apr; 38(6):773-8. PubMed ID: 11937310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.
    Faradmal J; Kazemnejad A; Khodabakhshi R; Gohari MR; Hajizadeh E
    Asian Pac J Cancer Prev; 2010; 11(2):353-8. PubMed ID: 20843115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
    Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
    Martín M; Ruiz A; Muñoz M; Balil A; García-Mata J; Calvo L; Carrasco E; Mahillo E; Casado A; García-Saenz JA; Escudero MJ; Guillem V; Jara C; Ribelles N; Salas F; Soto C; Morales-Vasquez F; Rodríguez CA; Adrover E; Mel JR;
    Lancet Oncol; 2007 Mar; 8(3):219-25. PubMed ID: 17329192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
    Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
    Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
    Chan D; Yeo WL; Tiemsim Cordero M; Wong CI; Chuah B; Soo R; Tan SH; Lim SE; Goh BC; Lee SC
    Invest New Drugs; 2010 Dec; 28(6):859-65. PubMed ID: 19705063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.